SABCS 2023 | Management of ER+ breast cancer with checkpoint inhibitors

Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, comments on the Phase III CheckMate 7FL (NCT04109066) and KEYNOTE-756 (NCT03725059) trials of nivolumab and pembrolizumab respectively with neoadjuvant chemotherapy in patients with ER-positive breast cancer. Pathological complete response was improved in the checkpoint inhibitor arms of both trials and further event-free survival was analyzed in the latter trial. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.